Logo image of INSM

INSMED INC (INSM) Stock Fundamental Analysis

NASDAQ:INSM - Nasdaq - US4576693075 - Common Stock - Currency: USD

69.69  +0.73 (+1.06%)

After market: 70.5 +0.81 (+1.16%)

Fundamental Rating

3

INSM gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 567 industry peers in the Biotechnology industry. INSM may be in some trouble as it scores bad on both profitability and health. INSM is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

INSM had negative earnings in the past year.
In the past year INSM has reported a negative cash flow from operations.
In the past 5 years INSM always reported negative net income.
In the past 5 years INSM always reported negative operating cash flow.
INSM Yearly Net Income VS EBIT VS OCF VS FCFINSM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M -800M

1.2 Ratios

INSM has a Return On Assets (-45.12%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of -320.20%, INSM is doing worse than 74.96% of the companies in the same industry.
Industry RankSector Rank
ROA -45.12%
ROE -320.2%
ROIC N/A
ROA(3y)-43.52%
ROA(5y)-40.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INSM Yearly ROA, ROE, ROICINSM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

INSM has a better Gross Margin (76.43%) than 83.42% of its industry peers.
INSM's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for INSM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.05%
GM growth 5Y-1.46%
INSM Yearly Profit, Operating, Gross MarginsINSM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

INSM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for INSM has been increased compared to 1 year ago.
The number of shares outstanding for INSM has been increased compared to 5 years ago.
The debt/assets ratio for INSM has been reduced compared to a year ago.
INSM Yearly Shares OutstandingINSM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
INSM Yearly Total Debt VS Total AssetsINSM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

Based on the Altman-Z score of 1.04, we must say that INSM is in the distress zone and has some risk of bankruptcy.
INSM has a Altman-Z score of 1.04. This is in the better half of the industry: INSM outperforms 68.08% of its industry peers.
INSM has a Debt/Equity ratio of 3.95. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of INSM (3.95) is worse than 83.42% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.95
Debt/FCF N/A
Altman-Z 1.04
ROIC/WACCN/A
WACC9.97%
INSM Yearly LT Debt VS Equity VS FCFINSM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

A Current Ratio of 5.45 indicates that INSM has no problem at all paying its short term obligations.
INSM has a Current ratio (5.45) which is in line with its industry peers.
INSM has a Quick Ratio of 5.12. This indicates that INSM is financially healthy and has no problem in meeting its short term obligations.
INSM has a Quick ratio of 5.12. This is comparable to the rest of the industry: INSM outperforms 56.61% of its industry peers.
Industry RankSector Rank
Current Ratio 5.45
Quick Ratio 5.12
INSM Yearly Current Assets VS Current LiabilitesINSM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

7

3. Growth

3.1 Past

INSM shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.68%.
INSM shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.17%.
The Revenue has been growing by 21.65% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-4.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3.13%
Revenue 1Y (TTM)19.17%
Revenue growth 3Y24.49%
Revenue growth 5Y21.65%
Sales Q2Q%24.79%

3.2 Future

The Earnings Per Share is expected to grow by 24.46% on average over the next years. This is a very strong growth
Based on estimates for the next years, INSM will show a very strong growth in Revenue. The Revenue will grow by 66.07% on average per year.
EPS Next Y2.57%
EPS Next 2Y14.85%
EPS Next 3Y22.83%
EPS Next 5Y24.46%
Revenue Next Year28.31%
Revenue Next 2Y66.31%
Revenue Next 3Y72.27%
Revenue Next 5Y66.07%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
INSM Yearly Revenue VS EstimatesINSM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2B 4B 6B
INSM Yearly EPS VS EstimatesINSM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INSM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INSM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INSM Price Earnings VS Forward Price EarningsINSM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INSM Per share dataINSM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

INSM's earnings are expected to grow with 22.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.85%
EPS Next 3Y22.83%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INSM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INSMED INC

NASDAQ:INSM (4/25/2025, 8:15:57 PM)

After market: 70.5 +0.81 (+1.16%)

69.69

+0.73 (+1.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-20 2025-02-20/bmo
Earnings (Next)05-08 2025-05-08
Inst Owners112.91%
Inst Owner Change-60.65%
Ins Owners1.06%
Ins Owner Change4.34%
Market Cap12.67B
Analysts85
Price Target97.61 (40.06%)
Short Float %8.08%
Short Ratio6.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-6.79%
Min EPS beat(2)-11.19%
Max EPS beat(2)-2.38%
EPS beat(4)1
Avg EPS beat(4)-12.05%
Min EPS beat(4)-50.18%
Max EPS beat(4)15.57%
EPS beat(8)2
Avg EPS beat(8)-13.9%
EPS beat(12)4
Avg EPS beat(12)-10.22%
EPS beat(16)5
Avg EPS beat(16)-8.19%
Revenue beat(2)0
Avg Revenue beat(2)-0.97%
Min Revenue beat(2)-1.53%
Max Revenue beat(2)-0.41%
Revenue beat(4)1
Avg Revenue beat(4)-1.51%
Min Revenue beat(4)-4.81%
Max Revenue beat(4)0.7%
Revenue beat(8)2
Avg Revenue beat(8)-0.25%
Revenue beat(12)3
Avg Revenue beat(12)-0.28%
Revenue beat(16)5
Avg Revenue beat(16)-0.34%
PT rev (1m)0.12%
PT rev (3m)7.04%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.94%
EPS NY rev (1m)-0.87%
EPS NY rev (3m)-23.62%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)5.86%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)-9.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 34.84
P/FCF N/A
P/OCF N/A
P/B 44.4
P/tB 139.83
EV/EBITDA N/A
EPS(TTM)-5.59
EYN/A
EPS(NY)-5.45
Fwd EYN/A
FCF(TTM)-3.88
FCFYN/A
OCF(TTM)-3.76
OCFYN/A
SpS2
BVpS1.57
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -45.12%
ROE -320.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.43%
FCFM N/A
ROA(3y)-43.52%
ROA(5y)-40.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.05%
GM growth 5Y-1.46%
F-Score4
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 3.95
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 159.73%
Cap/Sales 6.03%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.45
Quick Ratio 5.12
Altman-Z 1.04
F-Score4
WACC9.97%
ROIC/WACCN/A
Cap/Depr(3y)113.37%
Cap/Depr(5y)86.53%
Cap/Sales(3y)4.8%
Cap/Sales(5y)4.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3.13%
EPS Next Y2.57%
EPS Next 2Y14.85%
EPS Next 3Y22.83%
EPS Next 5Y24.46%
Revenue 1Y (TTM)19.17%
Revenue growth 3Y24.49%
Revenue growth 5Y21.65%
Sales Q2Q%24.79%
Revenue Next Year28.31%
Revenue Next 2Y66.31%
Revenue Next 3Y72.27%
Revenue Next 5Y66.07%
EBIT growth 1Y-15.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.2%
EBIT Next 3Y25.3%
EBIT Next 5YN/A
FCF growth 1Y-28.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-27.53%
OCF growth 3YN/A
OCF growth 5YN/A